Engineered immune cells take aim at Hard-to-Treat cancers

NCT ID NCT07224568

Not yet recruiting Disease control Sponsor: Seattle Children's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The study aims to see if the modified cells can be made safely and what side effects they cause. Up to 21 participants will receive the cells through an IV after a short course of chemotherapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for YOLK SAC TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Endodermal Sinus Tumor hepatocellular carcinoma liposarcoma Liver Neoplasms neoplasm rhabdomyosarcoma yolk sac tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA LIPOSARCOMA LIVER CELL CARCINOMA RHABDOMYOSARCOMA SOLID TUMOR (EXCLUDING CNS) YOLK SAC TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fred Hutch Cancer Center

Seattle, Washington, 98109, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••